Aeglea BioTherapeutics Investor Presentation Deck
October 2023, 37 slides
  1. Aeglea BioTherapeutics
  2. Investor Presentation Decks
corporate overview ans | Aeglea BioTherapeutics
disclosures | Aeglea BioTherapeutics
targeting new heights in the treatment of tun | Aeglea BioTherapeutics
potential best in class lead programs | Aeglea BioTherapeutics
despite advances new approaches are needed to break the efficacy ceiling and improve convenience of | Aeglea BioTherapeutics
our strategy is built on three validated approaches to address unmet needs in | Aeglea BioTherapeutics
is building a potentially best in class pipeline with next generation and rational combinations cee am | Aeglea BioTherapeutics
spy | Aeglea BioTherapeutics
spy is designed to be a long acting anti i i i | Aeglea BioTherapeutics
spy is as potent and selective as in preclinical studies | Aeglea BioTherapeutics
spy has exhibited the half life of in | Aeglea BioTherapeutics
we aim to demonstrate the following for spy in the expected interim phase a | Aeglea BioTherapeutics
spy phase clinical trial design | Aeglea BioTherapeutics
expected phase interim data will validate if half life and is within predicted range as | Aeglea BioTherapeutics
a half life of days in a format is expected to offer a superior product profile for patients | Aeglea BioTherapeutics
expected interim data will also inform our ability to test induction exposure response relationship in phase | Aeglea BioTherapeutics
designed for fully induction dosing with upside efficacy potential | Aeglea BioTherapeutics
spy is designed to match favorable safety profile and low rate of | Aeglea BioTherapeutics
spy summary wot | Aeglea BioTherapeutics
spy | Aeglea BioTherapeutics
spy is designed to achieve the optimal product profile a i i | Aeglea BioTherapeutics
extensive discovery campaign pursued to identify an uncompromising a antibody a if format | Aeglea BioTherapeutics
a lead clones are highly potent and characteristically diverse in preclinical studies an a | Aeglea BioTherapeutics
spy is a potential best in class a | Aeglea BioTherapeutics
spy summary wot | Aeglea BioTherapeutics
targeted therapeutic combinations | Aeglea BioTherapeutics
is unique in its portfolio approach to evaluate multiple combination regimens i i | Aeglea BioTherapeutics
portfolio addresses the diverse of ree | Aeglea BioTherapeutics
study demonstrated power of combination therapy despite relative weakness of components | Aeglea BioTherapeutics
aims to build on this success with combinations of best in class from superior as | Aeglea BioTherapeutics
combination programs summary | Aeglea BioTherapeutics
corporate | Aeglea BioTherapeutics
leadership and bod | Aeglea BioTherapeutics
cash and anticipated milestones | Aeglea BioTherapeutics
thank you | Aeglea BioTherapeutics
transaction highlights | Aeglea BioTherapeutics
capitalization | Aeglea BioTherapeutics
See More
Aeglea BioTherapeutics
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Recent decks by Aeglea BioTherapeutics
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Mergers and Acquisitions
June 2023
See all presentations by Aeglea BioTherapeutics (14 decks)
Recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Mergers and Acquisitions
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io